REUTERS: Drug developer Neurotrope Inc's shares tumbled nearly 80per cent on Monday after the company said its experimental treatment for Alzheimer's disease did not meet the main goal of a mid-stage study.
This is the second time in just over two years that the treatment - Bryostatin-1 - failed to meet its targets, raising questions about the drug's future. The treatment, Bryostatin-1, did not show any significant difference in patients after 13 weeks compared with those on placebo, the company said on Monday.
Neurotrope said it intends to conduct a complete review of the data to determine next steps in the treatment's development. Alzheimer's disease, which affects parts of the brain that control thought, memory and language, is a progressive condition that could seriously disrupt a patient's ability to carry out daily activities.
Several drugmakers such as Eli Lilly, AstraZeneca Plc, Roche AG, Pfizer Inc, Merck and Co Inc and Johnson and Johnson have all previously failed in their attempts to develop treatments for the memory-robbing disease.Source: Reuters
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: The Straits Times - 🏆 8. / 63 Read more »
Deal with Taleban would have failed Afghanistan - and the USWASHINGTON - President Donald Trump's sudden revelation and cancellation of a secretly planned meeting in the United States with Afghan President Ashraf Ghani and Taleban leaders pulled back the US from signing a peace deal that many predicted would take a disastrous turn not only for Afghanistan but for the US as well.. Read more at straitstimes.com.
Source: The Straits Times - 🏆 8. / 63 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »